INC Research Strengthens Cardiovascular Research Capabilities with Appointment of Dr. Martin Sullivan as Executive Medical Director, Cardiovascular Medicine
(Thomson Reuters ONE) -
Distinguished cardiologist brings extensive experience in novel approaches
for treating patients with cardiovascular disease
Raleigh, N.C., Oct. 14, 2013 - INC Research, a therapeutically focused global
clinical research organization (CRO) with a Trusted Process® for delivering
reliable results, today announced the appointment of Martin Sullivan, MD, as
Executive Medical Director, Cardiovascular Medicine. Dr. Sullivan will leverage
his strong therapeutic insight into clinical trials involving cardiovascular
drugs and devices for a wide range of conditions to provide hands-on medical
management of the Company's cardiology trials and to drive clinical development
globally in this key therapeutic area.
"The prevalence of cardiovascular diseases provides significant opportunity for
the development of new therapies to improve the health and overall wellbeing of
many patients worldwide," said Sally Osmond, Executive Vice President and
General Manager, Cardiovascular and Endocrinology Clinical Development at INC
Research. "Marty is a highly respected cardiologist with extensive experience
both in practice and in clinical development, having implemented more than 100
clinical research projects. We're thrilled to have a thought leader of his
caliber to lead development of these complex trials."
Board-certified in both internal medicine and cardiovascular diseases, Dr.
Sullivan brings more than 25 years of experience in medical practice and
clinical research to INC Research. Prior to joining the Company, he worked as a
research consultant specializing in noninvasive cardiology. He earned his
medical degree at The Ohio State University and received his post-graduate
cardiology training at Duke University where he remained on faculty, later
becoming an Associate Professor of Medicine. Dr. Sullivan has had a long and
distinguished career at a variety of institutions, including stints as the
Director of the Duke Center for Integrative Medicine; Director of Cardiovascular
Research at the Heartland Regional Medical Center in St. Joseph's, Missouri; and
a Senior Research Consultant in the Division of Cardiology at the University of
North Carolina. For his contributions to cardiovascular research, Dr. Sullivan
was named an Established Investigator of the American Heart Association.
Dr. Sullivan will present "New Frontiers in Cardiovascular Research: Biologic
Therapies - Using stem cells, gene therapy, and growth factors to treat patients
with cardiovascular disease," a complimentary webinar, on Wednesday, Oct. 16, at
3 p.m. GMT/10 a.m. EDT. The webinar will cover the current state of research for
cardiovascular diseases and will discuss novel approaches in clinical
development, such as cell therapies, growth factors and gene therapies that are
being used to regrow cells, repair damage and improve cardiovascular health
without surgery. Click here to register.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to us
for a complete range of customized Phase I to IV programs in all therapeutic
areas and patient populations. Our Trusted Process® methodology and therapeutic
foresight lead customers to better-informed product development decisions, while
our solid site relationships are a critical success factor in delivering
clinical trial results on time and on budget. INC was ranked "Top CRO" by sites
worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey.
INC Research is headquartered in Raleigh, NC. For more information, please visit
www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1735540]
Unternehmensinformation / Kurzprofil:
Datum: 14.10.2013 - 19:17 Uhr
Sprache: Deutsch
News-ID 305880
Anzahl Zeichen: 4737
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Strengthens Cardiovascular Research Capabilities with Appointment of Dr. Martin Sullivan as Executive Medical Director, Cardiovascular Medicine"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
